Big beasts drive biopharma valuations higher in 2021
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
A bad year to be an American medtech
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Medtech developments over the Christmas period
The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.
Argenx’s independent streak approaches its biggest test
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Free to download now: Evaluate Vantage’s 2022 Preview
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.
Covid-19 tests versus Omicron
The new variant might be able to dodge one of the PCR tests authorised in the US, the FDA says.
Mitsubishi's Medicago heads for the Covid-19 booster queue
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Big beasts drive biopharma valuations higher in 2021
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
A bad year to be an American medtech
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Medtech developments over the Christmas period
The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.
Argenx’s independent streak approaches its biggest test
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Free to download now: Evaluate Vantage’s 2022 Preview
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.
Covid-19 tests versus Omicron
The new variant might be able to dodge one of the PCR tests authorised in the US, the FDA says.
Mitsubishi's Medicago heads for the Covid-19 booster queue
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
